Valued at a market cap of $19 billion, Incyte Corporation (INCY) is a biopharmaceutical company based in Wilmington, Delaware. It discovers, develops, and commercializes proprietary therapeutics for severe unmet medical needs.
This healthcare company has considerably outperformed the broader market over the past 52 weeks. Shares of INCY have soared 49.2% over this time frame, while the broader S&P 500 Index ($SPX) has gained 24.3%. However, on a YTD basis, the stock is down 3.6%, lagging SPX’s 8.1% rise.